Cargando…
New oral anticoagulants: discussion on monitoring and adherence should start now!
New oral anticoagulants (NOACs) have been introduced to improve anticoagulant therapy worldwide, but safe implementation may require additional measures. First, optimization of dose adjustment based on therapeutic levels of the drug may be more appropriate than fixed dose therapy. The development an...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3716685/ https://www.ncbi.nlm.nih.gov/pubmed/23809888 http://dx.doi.org/10.1186/1477-9560-11-8 |
_version_ | 1782277575789248512 |
---|---|
author | ten Cate, Hugo |
author_facet | ten Cate, Hugo |
author_sort | ten Cate, Hugo |
collection | PubMed |
description | New oral anticoagulants (NOACs) have been introduced to improve anticoagulant therapy worldwide, but safe implementation may require additional measures. First, optimization of dose adjustment based on therapeutic levels of the drug may be more appropriate than fixed dose therapy. The development and implementation in quantitative laboratory assays will enable further dose optimization. Second, non-adherence to medication is a potential threat to the safe use of NOACs. Since cardiovascular medication may not be optimally used in about 50% of patients, procedures to improve adherence are imperative, also for NOAC therapy and in particular in elderly patients. |
format | Online Article Text |
id | pubmed-3716685 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-37166852013-07-20 New oral anticoagulants: discussion on monitoring and adherence should start now! ten Cate, Hugo Thromb J Editorial New oral anticoagulants (NOACs) have been introduced to improve anticoagulant therapy worldwide, but safe implementation may require additional measures. First, optimization of dose adjustment based on therapeutic levels of the drug may be more appropriate than fixed dose therapy. The development and implementation in quantitative laboratory assays will enable further dose optimization. Second, non-adherence to medication is a potential threat to the safe use of NOACs. Since cardiovascular medication may not be optimally used in about 50% of patients, procedures to improve adherence are imperative, also for NOAC therapy and in particular in elderly patients. BioMed Central 2013-06-28 /pmc/articles/PMC3716685/ /pubmed/23809888 http://dx.doi.org/10.1186/1477-9560-11-8 Text en Copyright © 2013 ten Cate; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Editorial ten Cate, Hugo New oral anticoagulants: discussion on monitoring and adherence should start now! |
title | New oral anticoagulants: discussion on monitoring and adherence should start now! |
title_full | New oral anticoagulants: discussion on monitoring and adherence should start now! |
title_fullStr | New oral anticoagulants: discussion on monitoring and adherence should start now! |
title_full_unstemmed | New oral anticoagulants: discussion on monitoring and adherence should start now! |
title_short | New oral anticoagulants: discussion on monitoring and adherence should start now! |
title_sort | new oral anticoagulants: discussion on monitoring and adherence should start now! |
topic | Editorial |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3716685/ https://www.ncbi.nlm.nih.gov/pubmed/23809888 http://dx.doi.org/10.1186/1477-9560-11-8 |
work_keys_str_mv | AT tencatehugo neworalanticoagulantsdiscussiononmonitoringandadherenceshouldstartnow |